IL-12 is a 70-kDa cytokine comprised of two disulfide-linked proteins (p35 and p40) and is essential for the initiation of effective immune response. Granulocyte-colony stimulating factor (G-CSF) affects the balance in the production of anti-inflammatory cytokines. We investigated the serum IL-12 p40 and IL-12 Mix (p40 and p70) production in 28 patients with B-cell lineage non-Hodgkin's lymphoma (NHL) treated with chemotherapy (e.g., CHOP regimen) with or without G-CSF administration and 8 healthy volunteers. We found that serum levels of IL-12 p40 (191.2±150.0 pg/ml) and IL-12 Mix (277.4 ±274.5 pg/ml) in the patients before chemotherapy were higher than those in the healthy volunteers (IL-12 p40: 76.4±25.3 pg/ml, IL-12 Mix:
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Introduction
Interleukin (IL)-12 is a heterodimeric cytokine produced by dendritic cells (DCs), macrophages, polymorphonuclear leukocytes, and keratinocytes (1) . IL-12 exerts multiple biologic activities that, besides NK cell activation, also include activation of CD8 + cytotoxic T lymphocytes (CTLs), differentiation of CD4 + T lymphocytes, induction of nitric oxide (NO) production by macrophages, and induction of type 1 responses by Th lymphocyte (2, 3) . IL-12 has been shown to possess potent anti-tumor activity in a wide variety of murine tumor models (4) (5) (6) (7) (8) . IL-12 is a 70-kDa cytokine comprised of two disulfide-linked proteins (p35, which is constitutively expressed, and p40, which is inducible) (9) . The genes encoding IL-12 p40 and p35 are located on different human and mouse chromosomes (10) . The highly coordinated expression of p40 and p35 genes to form IL-12 (also called p70) in the same cell type at the same time is essential for the initiation of effective immune response. The IL-12 p35 subunit is expressed ubiquitously, whereas expression of the p40 subunit is restricted to IL-12-producing cells (11) . The homodimer IL-12 p40 has been found in several studies to be a strong antagonist of IL-12-mediated effects, such as NK cell activity and IFN-γ production (12, 13).
Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic growth factor that stimulates neutrophil proliferation and function (14) . In animal models of infections, the administration of G-CSF increased neutrophil count, decreased bacterial load, and improved organ function and survival, as long as G-CSF was given before or, at the latest, immediately after the initiation of infection (15) . Therefore, the possibility that G-CSF affects the balance in the production of anti-inflammatory cytokines has been suggested (16) (17) (18) (19) (20) .
In the present study, we investigated the production of IL-12 p40, IL-12 Mix and other cytokines in patients with B-cell lineage non-Hodgkin's lymphoma (NHL) treated with CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) regimen with or without G-CSF administration. 
Patients and methods

Preclinical study
Patients' characteristics
Eighteen adult patients with B-cell lineage NHL were registered in the study between January 1999 to June 2003 at Hokkaido University Hospital and 10 other hospitals. All of the patients were informed of the purpose of the study, which was approved by the institutional review board. The characteristics of the 18 patients are summarized in Table 1 
Statistical analysis
Differences between groups were analyzed by Student's t test. Survival curves were plotted according to the method of Kaplan and Meier, and comparison of the curves was performed using the log-rank test. Overall survival (OS) was measured from the date of registration until death or last contact. Event-free survival (EFS) was measured from the date of registration until relapse after CR, death CR, or last contact, whichever occurred first. If a patient did not reach CR by induction chemotherapy, EFS was set at 0. Disease-free survival (DFS) was restricted to patients who achieved CR and was measured from attainment of CR until the date of relapse, death, or last contact, whichever occurred first.
Results
Serum IL-12 p40 and IL-12 Mix levels were increased in patients with non-Hodgkin's lymphoma.
We found that serum IL-12 p40 and IL-12 Mix levels in NHL patients before chemotherapy were higher than those in healthy volunteers (Table 2) . Serum IL-12 p40 and IL-12 Mix levels in healthy volunteers (n=8) were 76.4±25.3 pg/ml and 48.5±33.4 pg/ml, respectively, and those in NHL patients before chemotherapy (n=28) were 191.2±150.0 pg/ml and 277.4±274.4 pg/ml, p=0.04 and p=0.02, respectively. The levels in the 17 clinical stage Ⅲ-Ⅳ patients (IL-12 p40: 229.6±163.7 pg/ml, IL-12 Mix: 380.2±304.6 pg/ml) were significantly higher than those in healthy volunteers (P=0.01 and 0.0059, respectively).
Administration of G-CSF decreased serum IL-12 p40 and IL-12 Mix levels after chemotherapy.
To determine the effect of G-CSF on serum IL-12 p40 and IL-12 Mix levels, the patients were divided into a group administered G-CSF (CG group) and a group not administered G-CSF (C group). As shown in Fig.1 
Administration of G-CSF improved the survival of patients with advanced-stage non-Hodgkin's lymphoma who had decreased IL-12 p40 and IL-12 Mix levels.
We analyzed the association of clinical characteristics with IL-12 p40 and IL-12Mix levels.
Interestingly, serum IL-12 p40 level in CG group patients with clinical stages Ⅲ and Ⅳ was significantly decreased after chemotherapy (-95.6±131.1pg/ml) (16 courses) compared with that in C group patients with clinical stages Ⅲ and Ⅳ (-0.1±35.2 pg/ml) (10 courses) (P=0.035) (Fig.2a) .
However, serum IL-12 Mix level in CG group patients with clinical stages Ⅲ and Ⅳ was not significantly decreased after chemotherapy (-132.6±160.1pg/ml) (16 courses) compared with that in C group patients with clinical stages Ⅲ and Ⅳ (-37.0±75.2 pg/ml) (10 courses) (P=0.091) (Fig.2b) .
Serum IL-12 p70 levels could not be detected in almost all patients.
We analyzed the association of survival rate with administration of G-CSF. The overall survival (OS) at 24 months was not significantly different in the two groups (58.3% in C group vs 80.0% in CG group, P=0.67) (Figure 3-a) . However, the survival rates of G-CSF-treated patients at clinical Studies on IL-12 production by malignant B-cells suggest that the IL-12 p40 gene is constitutively transcribed in some lymphoma entities (FL, MZL), whereas p35 mRNA is always expressed.
In contrast to an early report that few cytokines are expressed in NHL (25) , several groups have
shown that a wide range of cytokines, at least at a transcriptional level, are expressed in NHL tissue (22, (26) (27) (28) . The present study highlights the potential significance of the administration of G-CSF affecting IL-12 p40 and IL-12 Mix levels in terms of tumor growth and patient survival. Previous studies reports suggested that IL-12 is only expressed in EBV-associated lymphomas (24,29).
However, Jones et al. detected transcripts in 60% of NHL cases and high levels of p40 were associated with a good prognosis, in those cases, although only a small group was analyzed (30).
Although we did not examine cytokine gene expression in the lymphoma cells, serum IL-12 p40 level was reduced in the group administered G-CSF and survival rates of G-CSF-treated patients at clinical stages Ⅲ and Ⅳ were superior to those of patients not treated with G-CSF.
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) plays an important role in Recently, the Dutch-Belgian Hemato-Oncology Coperative Group (HOVAN) group compared the effect of the cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen given every 3 weeks with the effect of the same regimen plus G-CSF in elderly patients with aggressive non-Hodgkin's lymphoma in a randomized study (42) . They found that the survival rate of patients who received the CHOP plus G-CSF regimen was better than that of patients who received the CHOP regimen. In the present study, the survival rate of patients at clinical stages Ⅲ and Ⅳ who received chemotherapy with G-CSF was better than that of patients who received chemotherapy without G-CSF. Also, IL-12 p40 level was significantly decreased in the chemotherapy with G-CSF group. We cannot explain the association between good survival rate and decrease in IL-12 p40
level. However, administration of G-CSF appears to influence survival rate by reducing immunosuppressive IL-12 p40 production in advanced-stage NHL patients. 
